Search the database for deliberate release of GM medicinal products
Displaying 1 - 1 of 1
| EU record number | Title | Company / Sponsor | Treated organism | Genetic modification |
|---|---|---|---|---|
| CYAD-211-001 | An open-label phase I, multi-center study to determine the recommended dose of the chimeric antigen receptor T-cell treatment CYAD-211 after a non-myeloablative preconditioning chemotherapy in multiple myeloma patients with relapsed or refractory disease. | Celyad | Humans | BCMA-CAR and ShRNA CD3ζ |